Medivir: Phase I part of the liver cancer trial completed - Redeye

Redeye comments on the conclusion of the phase I part of the ongoing phase I/IIa study of fostroxacitabine bralpamide in liver cancer (HCC). Medivir will not continue with the expansion cohort in the anti-PD-1 arm. We update our Base Case.

Länk till analysen i sin helhet: https://www.redeye.se/research/914548/medivir-phase-i-part-of-the-liver-cancer-trial-completed-2?utm_source=finwire&utm_medium=RSS